sermorelin peptide other names Latest Insights,helps your body create its own growth hormone production

Sermorelin peptide is a fascinating compound with a variety of designations and applications, often discussed in the context of growth hormone release and therapeutic interventions. Understanding its different names and classifications is crucial for comprehending its role in medicine and research. This article delves into the various sermorelin peptide other names, its scientific classifications, and its therapeutic implications, drawing upon expert knowledge and verifiable information.

At its core, sermorelin is a synthetic peptide that acts as an analogue of growth hormone-releasing hormone (GHRH). Specifically, it is a 29-amino acid polypeptide that mimics the action of the naturally occurring GHRH (1-29). This bioidentical nature is key to its function, as it stimulates the pituitary gland to release its own human growth hormone (hGH). This distinction is important; unlike direct hGH supplementation, sermorelin peptide therapy focuses on enhancing the body's intrinsic production of growth hormone.

Scientific Designations and Synonyms

The scientific community recognizes sermorelin under several technical names and synonyms, reflecting its chemical structure and biological activity. It is commonly referred to as sermorelin acetate, which denotes the salt form often used in pharmaceutical preparations. Another significant designation is GHRH(1-29), highlighting its specific amino acid sequence and its role as a fragment of the full GHRH molecule.

Further scientific nomenclature includes GROWTH HORMONE-RELEASING FACTOR (HUMAN)-(1-29)-PEPTIDE AMIDE RECOMBINANT. This lengthy description precisely details its origin (human), its functional component (1-29 amino acids of GHRH), its form (peptide amide), and its production method (recombinant). It is also listed under the International Nonproprietary Name (INN) as sermorelin.

In various databases and research contexts, you might encounter sermorelin listed with its chemical formula, such as C149H246N44O42S, and its PubChem CID, 16132413. Additional depositor-supplied synonyms can include Sermorelina, Sermoreline, Sermorelinum, and various alphanumeric codes like 86168-78-7 and 89243S03TE.

Brand Names and Historical Context

Historically, sermorelin was commercially manufactured and marketed in the United States under the brand name Geref. This was its primary approved use for many years, particularly as a diagnostic agent to assess pituitary function and, in some cases, for growth problems in children. The Geref (sermorelin) product was an injectable medication administered either subcutaneously or intravenously. Although Geref is no longer widely available, its historical significance is important for understanding the evolution of sermorelin's therapeutic applications.

Comparison with Other Peptides

Sermorelin is often discussed in conjunction with other peptides that influence growth hormone release. These include tesamorelin, ipamorelin, and CJC-1295. While all these compounds can stimulate the production of growth hormone, they possess distinct characteristics. Tesamorelin, for instance, is a GHRH analogue that has been specifically approved for managing HIV-associated lipodystrophy. Ipamorelin is another growth hormone-releasing peptide often compared to sermorelin, with some noting its more targeted action. CJC-1295 is also a GHRH analogue, but it typically has a longer half-life than sermorelin. Understanding these differences is crucial when evaluating sermorelin peptide therapy in comparison to other hormonal treatments. The shift towards sermorelin, ipamorelin, and tesamorelin represents a move from direct GH supplementation to more nuanced approaches that stimulate the body's natural hormonal production.

Therapeutic Applications and Research

The primary approved use for sermorelin has historically been in the diagnosis of growth hormone deficiency or growth failure in children. By stimulating the pituitary gland, it helps to evaluate the gland's ability to produce GH. Beyond its diagnostic role, sermorelin peptide therapy is also explored for its potential benefits in adults, often cited for promoting lean muscle development and supporting overall well-being by helping your body create its own growth hormone production.

It's important to note that while sermorelin was approved by the U.S. Food and Drug Administration (FDA) in 1997, its current status and availability for various therapeutic uses can be complex. For athletes, understanding the implications of using sermorelin is critical, as performance-enhancing substances are often scrutinized.

Key Takeaways

In summary, the sermorelin peptide is known by several names, including sermorelin acetate, GHRH(1-29), and Geref. It is a synthetic **